Remedy Pharmaceuticals

About:

Remedy Pharmaceuticals is a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders.

Website: http://remedypharmaceuticals.com

Top Investors: Broadview Ventures, Vertical GP-5

Description:

Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylurea receptor. The company was founded in 2004 and is based in New York, New York.

Total Funding Amount:

$18.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2004-01-01

Contact Email:

info(AT)remedypharmaceuticals.com

Founders:

David M. Geliebter, Sven M. Jacobson

Number of Employees:

11-50

Last Funding Date:

2017-01-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai